Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Grifols, S.A.NASDAQ: GRFS

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 37.6%

Gross margin was 37.6% in Q2 FY2026, down 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 37.2%, down 2.3 pp year over year. Over 3 fiscal years it narrowed by 0.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
37.6%+1.1 pp QoQ
Last fiscal yearDec 2025
35.7%-3.0 pp YoY
LTMJun 2026
37.2%-2.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.8 pp——
1 year-3.0 pp——
3 years-0.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
35.7%
Year-over-year change
-3.0pp

Gross Margin vs competitors

How GRFS compares with its peers on the latest reported figures

  • GRFS's LTM Jun 2026 gross margin of 37.2% is the 8th highest of the 9 companies compared; the peer median is 54.5%.
  • Its year-over-year change of -2.3 pp is the lowest of 9, against a peer median of +1.1 pp.
  • Over three fiscal years its change of -0.8 pp compares with a peer median of +0.2 pp.
GRFS Competitors Peer median
Gross Margin for GRFS and competitors
Company Period LTM level YoY 3-year change
TECHBio-Techne CorporationLTM Sep 202665.8% +0.4 pp-2.0 pp
ADMAADMA Biologics, Inc.LTM Jun 202664.7% +11.7 pp+34.5 pp
HAEHaemonetics CorporationLTM Jun 202657.4% +0.6 pp+2.4 pp
ABTAbbott LaboratoriesLTM Sep 202657.1% +3.1 pp+4.4 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202651.9% -0.9 pp-3.9 pp
BDXBecton, Dickinson and CompanyLTM Sep 202647.0% +1.6 pp+5.2 pp
QDELQuidelOrtho CorporationLTM Mar 202645.0% -2.0 pp-12.6 pp
GRFSGrifols, S.A.LTM Jun 202637.2% -2.3 pp-0.8 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 202634.6% +5.5 pp-62.9 pp
Peer median (excluding GRFS) 54.5%+1.1 pp+0.2 pp

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.